Infection risk in autoimmune hematological disorders with low-dose rituximab treatment.

Honglei WangSiyang YanHui LiuLijuan LiJia SongGuojin WangHuaquan WangYuhong WuZonghong ShaoRong Fu

Published in: Journal of clinical laboratory analysis (2020)

The G-CSF, nadir WBC count, and IgA level were protective factors of infection during rituximab treatment. Low-dose rituximab therapy in autoimmune hematological diseases does not increase infection risk compared with cyclophosphamide.

Keyphrases

low dose
diffuse large b cell lymphoma
high dose
hodgkin lymphoma
combination therapy
drug induced